BioPorto A/S (BIOPOR.CO)
BioPorto A/S operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Hellerup, CR, DK. The stock last traded at $1.20, up 3.45% on the session, giving a market capitalisation of $594.1M. Its beta of 1.38 implies it has historically moved more than the broad market.
BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker tests, research tools, and antibodies to medical professionals and scientists worldwide, with operations across Europe, North America, and Asia. Among its offerings is the neutrophil gelatinase-associated lipocalin (NGAL) test, a precise quantitative particle-enhanced turbidimetric immunoassay designed for use on automated chemistry analyzers. The company further provides monoclonal antibodies essential for scientific, pharmaceutical, and clinical investigations. Additionally, BioPorto produces enzyme-linked immunosorbent assay (ELISA) kits and a versatile rapid assay device tailored for custom lateral flow assay development. Established in 1917, the company is headquartered in Hellerup, Denmark.
BioPorto A/S is most often compared with the following Healthcare names: